Cargando…
NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial
Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth factor (FGF) 19 is a hormone that acts direct...
Autores principales: | Mayo, Marlyn J., Wigg, Alan J., Leggett, Barbara A., Arnold, Hays, Thompson, Alexander J., Weltman, Martin, Carey, Elizabeth J., Muir, Andrew J., Ling, Lei, Rossi, Stephen J., DePaoli, Alex M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128239/ https://www.ncbi.nlm.nih.gov/pubmed/30202819 http://dx.doi.org/10.1002/hep4.1209 |
Ejemplares similares
-
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
por: Harrison, Stephen A., et al.
Publicado: (2019) -
A real‐world observational cohort of patients with primary biliary cholangitis: TARGET‐primary biliary cholangitis study design and rationale
por: Levy, Cynthia, et al.
Publicado: (2018) -
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2023) -
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
por: Mayo, Marlyn J., et al.
Publicado: (2022) -
Correction to: Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
por: Mayo, Marlyn J., et al.
Publicado: (2023)